Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Amgen's share price for the quarter that ended in Sep. 2023 was $268.76. Amgen's Shares Outstanding (EOP) for the quarter that ended in Sep. 2023 was 535 Mil. Therefore, Amgen's market cap for the quarter that ended in Sep. 2023 was $143,813 Mil.
Amgen's quarterly market cap
declined
from Mar. 2023 ($129,167 Mil) to Jun. 2023 ($118,758 Mil) but then
increased
from Jun. 2023 ($118,758 Mil) to Sep. 2023 ($143,813 Mil).
Amgen's annual market cap
declined
from Dec. 2020 ($132,963 Mil) to Dec. 2021 ($125,601 Mil) but then
increased
from Dec. 2021 ($125,601 Mil) to Dec. 2022 ($140,250 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Amgen's Enterprise Value for Today is $168,405 Mil.
Amgen Market Cap Historical Data
The historical data trend for Amgen's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Amgen Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Market Cap
122,564.23
142,568.80
132,962.74
125,600.75
140,249.76
Amgen Quarterly Data
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Market Cap
120,250.90
140,249.76
129,167.03
118,758.50
143,813.48
Competitive Comparison
For the Drug Manufacturers - General subindustry, Amgen's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen Market Cap Distribution
For the Drug Manufacturers industry and Healthcare sector, Amgen's Market Cap distribution charts can be found below:
* The bar in red indicates where Amgen's Market Cap falls into.
Amgen Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Amgen's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen (NAS:AMGN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Amgen Market Cap Related Terms
Thank you for viewing the detailed overview of Amgen's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amjevita (biosimilar Humira).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
3.04(1.14%) Volume: 2,499,855 4:00PM EST
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
AMGN has been successfully added to your 